Return to program book search
Merkel Cell Carcinoma: Diagnosis, Management & Controversies
Saturday, March 22
10:00 AM - 12:00 PM
Christopher K. Bichakjian, MD, FAAD
- Klaus J. Busam, MD
- Marcus L. Frohm, MD, FAAD
- Paul Nghiem, MD, PhD, FAAD
- Monique Verhaegen
Following this course, the attendee should be able to:
- Identify areas of consensus and controversy regarding the clinical, pathologic, and prognostic characteristics of Merkel cell carcinoma.
- Utilize recent developments in the clinical management of Merkel cell carcinoma, including sentinel lymph node biopsy and adjuvant therapy, to guide the multidisciplinary care of this malignancy.
- Analyze recent scientific data on the pathogenesis of Merkel cell carcinoma in relation to outcomes and emerging therapies.
Merkel cell carcinoma (MCC) is a polyomavirus-associated skin cancer with a higher disease-specific mortality than melanoma and an increasing incidence of ~1600 cases/year in the US. Clinical management is challenging due to the lack of evidence-based data and wide-ranging treatment recommendations in the literature. Multidisciplinary care is frequently indicated and strongly encouraged. This session will focus on current concepts in the diagnosis and management of MCC and highlight areas of consensus and controversy. Recent scientific advances in the pathogenesis of MCC and the potential future therapeutic implications will be reviewed.
|Saturday, March 22|
|10:00 AM||Introduction / Dr. Bichakjian|
|10:05 AM||Pathologic Diagnosis and Features, and Prognostic Implications / Dr. Busam|
|10:25 AM||Treatment of the Primary Tumor Site / Dr. Frohm|
|10:45 AM||Merkel Cell Polyomavirus, Immunity, and Targeted Therapy / Dr. Nghiem|
|11:05 AM||Contemporary Management and Outcomes / Dr. Bichakjian|
|11:25 AM||Bench to Bedside: Targeting the Apoptotic Machinery / Dr. Verhaegen|
|11:45 AM||Questions and Answers / All faculty|